Scaling CRISPR Gene Correction for Sickle Cell Disease

Researchers establish a clinical-scale, nonviral manufacturing process that directly repairs the disease-causing HBB mutation in autologous stem cells

November 9, 2026
3 min

The Medicine Maker

At a Glance

Category	Detail
Condition	Clinical topic addressed by the source article: Scaling CRISPR Gene Correction for Sickle Cell Disease
Key Mechanisms	Mechanisms or clinical associations described in the source article.
Target Population	Patients or participants described in the source article.
Care Setting	Clinical-scale cell manufacturing; products have been manufactured for two participants in an ongoing Phase I/II clinical trial. The therapy is investigational.

Key Highlights

CRISPR_SCD001 is designed to repair the disease-causing HBB mutation rather than add an anti-sickling gene or edit a regulatory region to increase fetal hemoglobin.
The manufacturing process includes cell culture, electroporation with CRISPR-Cas9 and corrective DNA, washing, cryopreservation, and product testing before release.
Across full-scale lots, average CD34-positive cell purity was 89% and viability was 84%; an average of 22% of HBB alleles were corrected.
In vitro differentiated red blood cells showed sickle hemoglobin decreasing from 89% to 22%, with adult and fetal hemoglobin reaching 39% and 40%, respectively.
Products have been manufactured for two participants in an ongoing Phase I/II trial assessing safety, engraftment, and persistence of corrected cells.

Guideline-Based Recommendations

Diagnosis

Management

Monitoring & Follow-up

Risks

Editing was detected at one previously identified off-target intergenic site at an average frequency of 4%.
No HBB–off-target translocations were detected above the assay's 0.01% detection threshold; normal karyotypes were reported in the two lots assessed.
In mice, edited human cells engrafted at lower levels than unedited controls, but remained present in multiple hematopoietic tissues after 16 weeks. Investigators reported no noteworthy treatment-related toxicity or abnormal tissue changes.

Patient & Prescribing Data

People with sickle cell disease; the article reports that products were manufactured for two participants in an ongoing Phase I/II trial.

The therapy uses a patient's own mobilized peripheral blood CD34-positive cells, edited ex vivo with CRISPR-Cas9 and a corrective DNA template, and intended to be returned after conditioning. The article provides no dosing or prescribing instructions.

Clinical Best Practices

The reported manufacturing process tests the edited, cryopreserved product before release.
The study evaluated cell purity, viability, HBB correction, insertions or deletions, off-target editing, translocations, and karyotypes.
Clinical safety, engraftment, and persistence are being assessed in the ongoing Phase I/II trial.